Alert detail

LCD L39040: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — WPS

Policy ID: LCD-L39040Specialty: OncologyAdded: 6/5/2026Effective: April 18, 2024lcd
Routine

What changed

Updates on lab tests for inherited cancer syndromes effective April 2024.

Who’s affected: Oncology billing teams · Effective: April 18, 2024

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 49 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.

LCD L39040: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — WPS